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APOCALYPSE NOW: THE END OF
MODERN MEDICINE AS WE KNOW IT
Gentlemen, it is the microbes who will
have the last word. [Messieurs, c’est les
microbes qui auront le dernier mot].
– Louis Pasteur, 1822–1895
The last 200 years have seen a dramatic
reduction in the prevalence and sever-
ity of microbial infections, due to the
implementation of groundbreaking mea-
sures ranging from improved sanitation
and hygiene and the introduction of asep-
tic techniques to the development of suc-
cessful vaccines and the discovery of effec-
tive antibiotics. Devastating infections that
were common until the late nineteenth cen-
tury such as cholera, diphtheria, plague,
syphilis, tuberculosis, and typhoid came
into the reach of effective control, at least
in developed countries, and with a min-
imized risk of wound infections surgical
procedures began to revolutionize modern
medicine. Antibiotics, in particular, radi-
cally transformed the treatment and pre-
vention of microbial infections and have
saved millions of lives since their intro-
duction (1). However, antibiotic usage is
invariably linked to the selective pressure
it exerts on the target organism to develop
escape strategies (2).
We are at present witnessing how the
pendulum begins to swing backwards,
with anti-microbial resistances develop-
ing on an unprecedented global scale.
New classes of Gram-positive and Gram-
negative “superbugs” are emerging and
spreading at an alarming rate, some of
which are virtually insusceptible to all
available drugs (3–5). The once apocalyp-
tic vision of a “post-antibiotic era” where
common infections and minor injuries
may result untreatable and eventually fatal
is rapidly becoming a real possibility (1,
2, 6, 7), heralding what Margaret Chan,
Director-General of the WHO, in 2012
called “the end of modern medicine as we
know it.” The appearance of multidrug-
resistant bacteria has been identified by
the WHO, the Centers for Disease Con-
trol and Prevention (CDC) in the USA and
their European counterpart, the ECDC,
as one of the major global health chal-
lenges humankind is facing in the twenty-
first century (8–10). According to Sally
Davies, the UK Chief Medical Officer,
“there are few public health issues of
greater importance than anti-microbial
resistance in terms of impact on society”
(11).
There is now an urgent call for anti-
microbial stewardship programs that aim
to prescribe antibiotics more prudently,
and to tailor their use to defined patient
groups who will benefit most. The fact
that the prevalence of resistance appears
to correlate directly with antibiotic con-
sumption across different countries (12)
argues in favor of the immediate effec-
tiveness of such tightly controlled pro-
grams. As highlighted in a recent Outlook
issue in Nature, “the potential to save lives
with faster and more targeted diagnoses,
decrease unnecessary and often incorrect
prescriptions, and even help identify early
on where bacterial resistance could occur,
will have a drastic effect on the way patients
are treated” (13).
MISSION IMPOSSIBLE: THE
FUNDAMENTAL FLAWS OF
CONVENTIONAL DIAGNOSIS
When it concerns the search for
pathogenic organisms suspected in
the diseased body, in the first
instance bacteria, then during con-
ventional microscopic examination
carried out without special prepa-
rations and artifices one encoun-
ters the most substantial, at times
virtually insurmountable, obstacles.
[Wenn es sich nun darum han-
delt, die im erkrankten Körper ver-
mutheten pathogenen Organismen,
zunächst Bacterien, aufzusuchen, so
begegnet man bei der gewöhn-
lichen ohne besondere Vorbereitun-
gen und Kunstgriffe ausgeführten
mikroskopischen Untersuchung den
erheblichsten, stellenweise geradezu
unübersteiglichen Hindernissen]. –
Robert Koch, 1843–1910 (14)
More than a century after Robert Koch’s
landmark discovery of the causative agents
of anthrax, cholera, and tuberculosis,
the diagnosis of suspected infections still
depends largely on the definitive identifi-
cation of the likely pathogen in biological
samples. However, standard microbiolog-
ical culture is inefficient and slow (typi-
cally >1–2 days, for a confirmed diagnosis
of tuberculosis >4 weeks), and in many
cases no organism can be grown despite
Abbreviation: HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate.
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clinical signs of infection, indicating that
conventional diagnostic methods are not
specific and/or rapid enough to target
therapy (15–17). Early management of
patients with acute symptoms who require
immediate medical intervention, includ-
ing virtually all hospital-based infections,
thus remains largely empirical. As direct
consequence, the fundamental uncertainty
about the real cause underlying the clinical
signs observed leads to inappropriate and
unnecessary treatments exposing patients
to drug-related side effects; raising the
risk of opportunistic, chronic, or recurrent
infections; and contributing to the emer-
gence and spread of multidrug resistance
(1–7). This dilemma eventually results
in potentially avoidable patient morbid-
ity/mortality, and imposes a considerable
burden on health care systems and societies
(8–11). There remains an unmet clinical
need for rapid and accurate diagnostic tests
for patients with acute infections. Accord-
ing to Kessel and Sharland (18), “new tech-
nology focusing on rapid diagnosis of spe-
cific bacteria and resistance genes, along
with combination biomarkers indicating
bacterial or viral infections, especially if
adapted to near patient testing, could have
a major impact on targeting appropriate
antibiotic treatment.”
In order to circumvent the almost
insurmountable obstacles of a rapid and
accurate identification of the causative
pathogen by traditional microbiological
techniques, efforts are being made to
utilize state-of-the-art molecular meth-
ods. Approaches based on the detec-
tion of microbial nucleic acids, cell wall
constituents, or other unique features
of distinct pathogens by PCR, chro-
matography, or mass spectrometry cer-
tainly complement culture-based tests
and speed up microbial identification,
yet they require considerable resources
and may not be applicable to primary
care or home settings (19–23). More-
over, they do not provide information
about the pathogenicity of the identi-
fied species and its interaction with the
host. Of note, neither microbiological nor
molecular methods discriminate between
pathogens causing disease, asymptomatic
carriage, and sample contaminants, and
thus even positive test results require exten-
sive interpretation by the treating physician
(24–26).
There is a plethora of disease-related
markers that are commonly assessed by
clinicians to aid a correct diagnosis, rang-
ing from basic blood and urine parameters
to indicators of tissue damage, tumor pro-
gression and autoimmunity, among others.
However, there is a conspicuous paucity
of biomarkers for accurate diagnosis of
microbial disease. Current biomarkers of
inflammation such as C-reactive protein
(CRP) or procalcitonin (PCT) are often
not sensitive or specific enough and are
only poor surrogates for acute infections
(22, 27, 28). The vast majority of research
on novel diagnostics has so far focused on
identifying individual factors and assess-
ing their performance in isolation. Yet,
it may come as no surprise that none of
these proposed parameters have reached
sufficient discriminatory power on their
own, given the complex and multifactorial
processes underlying local and systemic
inflammatory responses to a broad range
of pathogens (29, 30). As a result, neither
the direct identification of the causative
pathogen nor the measurement of cur-
rently used biomarkers of inflammation is
sufficiently accurate or rapid for a reliable
point-of-care diagnosis of acute microbial
infection.
QUANTUM OF SOLACE: EXPLOITATION
OF PATHOGEN-SPECIFIC HOST
RESPONSES FOR NOVEL DIAGNOSTICS
The immune system appears to have
originated as a set of effector cells
having multiple distinct receptors
that discriminate self from infec-
tious non-self by recognition of pat-
terns found exclusively on microor-
ganisms. – Charles A. Janeway, Jr.,
1943–2003 (31)
Key to developing better and stratified
approaches to treating infection is a
detailed understanding of the intricate
host–pathogen relationships in disease, in
order to exploit the unique sophistica-
tion of the human immune system for
diagnostic and therapeutic purposes (32,
33). In a radical departure from current
practice, our research is based upon the
premise that each type of infection evokes a
distinct pathogen-specific host response –
what we refer to as “immune fingerprint.”
A patient’s early anti-microbial response
itself is likely to provide far more detailed
insight into the true cause and sever-
ity of acute infections than conventional
methods, independently of the subsequent
clinical course of the disease (34). The
human immune system is a highly complex
network of interdependent cellular and
humoral players that has evolved over mil-
lions of years in order to survey the body for
potentially hazardous structures and initi-
ate an appropriate defense. The commu-
nication with invading micro-organisms
thus occurs at multiple levels, giving rise
to a plethora of biomarkers of potential
relevance for diagnostic purposes. Differ-
ent pathogens interact uniquely with dif-
ferent components of the innate immune
system due to the efficient self/non-self dis-
crimination based on conserved microbial
signals such as non-methylated bacterial
DNA, bacterial flagella, and cell wall con-
stituents. These structures are typically rec-
ognized by members of the Toll-like recep-
tor family and/or other pattern recogni-
tion receptors expressed by sentinel cells
(35–37). However, there is also emerg-
ing evidence that certain types of innate
or “unconventional” T-cells such as γδ T-
cells and mucosal-associated invariant T
(MAIT) cells are able to detect common
microbial metabolites through their T-cell
receptors, by sensing intermediates of the
non-mevalonate and riboflavin biosynthe-
sis pathways that are unique to certain types
of microorganisms (38, 39).
Vγ9/Vδ2 T-cells represent a unique
subpopulation of human T-cells (40, 41)
that appears to have a particularly cru-
cial role in contributing to immune fin-
gerprints of diagnostic relevance (34). This
is due to their exquisite responsiveness to
the microbial isoprenoid precursor (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMB-PP) that is produced by the
majority of Gram-negative pathogens and
a large proportion of Gram-positive species
such as Clostridium difficile, Listeria mono-
cytogenes, and Mycobacterium tuberculosis,
while it is not found in other bacteria
including staphylococci and streptococci
as well as fungi (42–44). The rapid and
sensitive response of Vγ9/Vδ2 T-cells to a
broad range of pathogens evokes Janeway’s
criteria for a “pathogen-associated mol-
ecular pattern” in that HMB-PP is an
invariant metabolite in many different
species that is essential in the microbial
physiology but absent from the human
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host (43, 45). Bacterial extracts prepared
from HMB-PP producing species typically
activate Vγ9/Vδ2 T-cells much stronger
than extracts prepared from HMB-PP
deficient micro-organisms (42, 44, 46),
and peripheral and/or local Vγ9/Vδ2 T-
cell levels are often elevated in patients
infected with defined HMB-PP producing
pathogens (43, 47). Elegant proof of con-
cept for this responsiveness comes from
the demonstration that HMB-PP produc-
ing wildtype L. monocytogenes activate
Vγ9/Vδ2 T-cells far better, both in vitro
(48) and in primate models in vivo (49),
than genetically engineered L. monocyto-
genes that are identical to the parental
strain except for an inability to pro-
duce HMB-PP. Similarly, overexpression of
HMB-PP synthase through genetic manip-
ulation increases the stimulatory poten-
tial of bacteria such as E. coli, L. mono-
cytogenes, M. tuberculosis, and Salmonella
enterica on Vγ9/Vδ2 T-cells in vitro (42,
46, 48, 50, 51) and in vivo (52). Our
own data demonstrate that even in het-
erogeneous patient cohorts infected with
a whole spectrum of diverse bacteria,
differences in Vγ9/Vδ2 T-cell frequencies
between patients with microbiologically
confirmed infections caused by HMB-PP
producing and HMB-PP deficient species
remain apparent. This is true both for peri-
toneal dialysis patients with acute peritoni-
tis as an exemplar of localized immune
responses restricted to the peritoneal cav-
ity (34, 46, 53), as well as on a sys-
temic level in the peripheral blood of
critically ill patients with severe sepsis
(54). Most importantly, studies in patients
with acute peritonitis suggest that a diag-
nostic test measuring local Vγ9/Vδ2 T-
cells on the first day of presentation
with acute symptoms may not only indi-
cate the presence of Gram-negative (pre-
dominantly HMB-PP producing) bacteria
but also identify patients at an increased
risk of inflammation-related downstream
complications (34).
The exquisite responsiveness of
Vγ9/Vδ2 T-cells and other unconven-
tional T-cells to microbial metabolites
shared by certain pathogens but not
by others identifies these cell types as
key constituent of diagnostically relevant
immune fingerprints at the point of care.
This is especially the case when Vγ9/Vδ2
T-cell levels are assessed locally and when
they are combined with other powerful dis-
criminators such as peritoneal proportions
of neutrophils, monocytes, and CD4+
T-cells in the inflammatory infiltrate as
well as intraperitoneal concentrations of
certain soluble immune mediators (34)
(Figure 1). Such a combination with
further parameters provides additional
information as to the precise nature of
the causative pathogen, for instance to
distinguish between immune responses
induced by Gram-negative (LPS produc-
ing) and Gram-positive (LPS deficient)
bacteria, and is also likely to help increase
sensitivity owing to the age and gender-
dependent variability of Vγ9/Vδ2 T-cell
levels (55). Pathogen-specific immune
fingerprints that discriminate between
certain subgroups of patients (e.g., with
Gram-negative vs. Gram-positive bacterial
infections) can be determined within hours
of presentation with acute symptoms, long
before traditional culture results become
available, and by guiding early patient
FIGURE 1 | Local immune fingerprints in peritoneal dialysis patients on the day of presentation with acute peritonitis. Shown are cellular and humoral
biomarkers that are associated with the presence of Gram-positive or Gram-negative bacteria and that may be exploited for novel diagnostic tests (34).
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management and optimizing targeted
treatment will contribute to improv-
ing outcomes and advancing antibiotic
stewardship. It remains to be investigated
how much these findings on diagnostic
immune fingerprints in peritoneal dialysis
patients can be extended to other local
or systemic scenarios to diagnose infec-
tions at the point of care, and whether
they can also be applied to monitoring the
course of the disease and the response to
treatment.
Applied research on γδ T-cells has so
far focused predominantly on their use for
novel immunotherapies against different
types of cancers (56–58). Thirty years after
the unexpected cloning of the TCRγ chain
(59, 60) and 20 years after the first descrip-
tion of microbial “phosphoantigens” as
specific activators of human Vγ9/Vδ2 T-
cells (61, 62), the diagnostic potential of γδ
T-cells is only beginning to unfold (34, 47,
63, 64).
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